Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with ...

The National Cancer Institute estimates that in the United States, slightly over 35,000 people will be diagnosed with multiple myeloma by the end of 2024 ... The early stages of kidney disease ...

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

More information: Emma Verheye et al, A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages, Journal of Hematology & Oncology (2024).

Historically, we evaluated myeloma through monoclonal proteins or ... out with a decision that MRD will be used as a surrogate end point. They're open to that as a surrogate end point for drug ...

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.